FDA

Oct 11, 2018

Cytosen Therapeutics and KBI Biopharma pair up to manufacture NK cells and Nanoparticles  CytoSen Therapeutics and KBI Biopharma paired up to manufacture therapeutic Natural Killer Cell by using a closed system manufacturing process. According to the initial collaboration, KBI will be subjected to manufactur...

Oct 09, 2018

FDA approves transthyretin amyloidosis therapy of Akcea, Ionis Patients with an orphan, hereditary disease that is transthyretin amyloidosis with a second new treatment option are available after the Food and Drug Administration approved Akcea Therapeutics and Ionis Pharmaceuticals' Tegsedi.  As Tegsedi is approved,...

Oct 03, 2018

Millions of people get bad side-effects when trying to withdraw antidepressants. The All Party Parliamentary Group for Prescribed Drug Dependence review shows half of the patients have withdrawal symptoms and for half of these, the symptoms will be severe. The patients should be properly warned for the same.The revi...

Sep 27, 2018

Ceribell raises USD 35 Million in series B round Ceribell, Emergency EEG maker raised USD 35 million for commercializing its EEG system that can rapidly diagnose patients, who are supposed of not having convulsive seizures with no visual symptoms for the use in neurological intensive care units and emergency rooms. ...

Sep 25, 2018

The interleukin-33 antibody of AnaptysBio passes midstage test in asthma The pipeline drug, etokimab of AnaptysBio, has positive data in a third indication that adds asthma to one of its triumphs. The US-based company gets another proof-of-concept study for the interleukin-33 (IL-33) inhibitor, because of phase 2a ...

Sep 18, 2018

Argenx gets green cue in phase 2 in primary immune thrombocytopenia The Belgian biotech, Argenx has cleared phase 2 data on efgartigimod in primary immune thrombocytopenia (ITP). The results that they received, indicate at the effectiveness of the antibody Fc fragment in patients with the autoimmune bleeding disord...

Sep 12, 2018

Aimovig of Amgen commence robust for migraine treatment The U.S. Food and Drug Administration (FDA) has given the approval to preventative migraine treatment, Aimovig of Amgen. Aimovig has a price of USD 6,900 per year, but according to analysis of sales, it gives information that migraine treatment is making its wa...

Sep 11, 2018

Nucala of GlaxoSmithKline exhibits splendid benefits to other IL-5 Inhibitors in Asthma, however flunks as a COPD Drug A Complete Response Letter is received by GSK from the U.S. Food and Drug Administration (FDA) for Nucala (mepolizumab) as COPD treatment. Nucala, which targets the IL-5 pathway, was initially appro...

Sep 05, 2018

Merck & Company virology business is flickering, after announcing two of its new HIV medications that bagged approval from the Food and Drug Administration (FDA). The oral medications, Pifeltro and Delstrigo, are taken once-daily with or without food for adult HIV-1 patients, who have never received antiretrovir...

Sep 04, 2018

Food and Drug Administration repudiates ADHD drug by Sunovion Sunovion’s ADHD drug for the treatment of attention-deficit hyperactivity disorder (ADHD) has not been accepted by the Food and Drug Administration, FDA. It is so because the drug for ADHD treatment in its current form needs additional clinical trials and...